Clinical trial · Interventional
Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer
Open-labeled, Randomized, Multicenter Phase III Study of Adjuvant Chemotherapy Comparing Bevacizumab Plus Cisplatin With Cisplatin Regimen in Malignant Pleural Effusion of Advanced Stage Non-Small-Cell Lung Cancer Patients
NCT01661790CI-TRIAL-00017242completedPhase 3Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To determine the efficacy and Safety of intrapleural Bevacizumab and cisplatin as a treatment for malignant pleural effusions (MPE) in patients with non-small cell lung cancer (NSCLC).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Pleural Effusion | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bevacizumab | Drug | Bevacizumab | ALIAS |
| Cisplatin | Drug | Cisplatin | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Bevacizumab & Cisplatin
- description
- Bevacizumab 300mg plus Cisplatin 30mg by intrapleural given every two weeks
- interventionNames
- Drug: Bevacizumab
- Drug: Cisplatin
- type
- ACTIVE_COMPARATOR
- label
- Cisplatin
- description
- Cisplatin 30mg by intrapleural given every two weeks
- interventionNames
- Drug: Cisplatin
Primary outcomes (1)
- measure
- Number of Participants With "Complete Response" and "Partial Response"
- timeFrame
- from randomization, This treatment was given every two weeks,responses were made by biweekly
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with advanced recurrent or progressive NSCLC proven cytohistologically * Karnofsky performance status (KPS) ≥60 * Life expectancy ≥ 2 months * No history of severe diseases of major organs including liver, heart, and kidney * No previous intrapleural therapy * Written informed consent Exclusion Criteria: * Active thoracic cavity or systemic bleeding * Active pleural or systemic infection. * Known sensitivity to Bevacizumab or Cisplatin * Refusal to participate in the study.
References
Publications (0)
Data not yet available
No reference posted for this study.